Skip to main content

Table 1 Demographics for healthy control and Parkinson’s disease participants

From: The effects of dopamine on digit span in Parkinson’s disease

 

HC

PD ALL

PD no-MCI

PD-MCI

PDD

p

N

22

64

28

22

14

 

Male/Female

8/14

35/29

13/15

14/8

8/6

 

Age (years)^

65.10 ± 6.89

68.36 ± 7.91

65.11 ± 7.21

69.14 ± 7.98

73.21 ± 6.68

* #

Education (years)^

16.81 ± 2.03

16.44 ± 2.42

16.48 ± 2.36

16.41 ± 2.56

16.71 ± 2.16

NS

Duration (years)^

n/a

5.92 ± 4.18

5.04 ± 3.47

6.64 ± 4.82

6.57 ± 4.38

NS

MDS-UPDRS III (OFF)^

n/a

37.47 ± 10.94

35.79 ± 10.53

34.00 ± 9.40

46.79 ± 9.37

# %

MDS-UPDRS III (ON)^

n/a

21.54 ± 11.11

19.81 ± 9.62

18.89 ± 10.32

29.85 ± 11.67

# %

LEDD^

n/a

695.4 ± 366.1

657.8 ± 382.7

831.8 ± 325.8

556.2 ± 344.1

NS

BDI^

3.64 ± 3.88

11.13 ± 8.34

9.26 ± 7.58

11.09 ± 7.08

13.92 ± 11.39

**

BAI^

2.68 ± 2.85

11.09 ± 8.80

11.43 ± 9.00

11.32 ± 8.34

10.04 ± 9.63

**

  1. PD Parkinson’s disease, PDD PD with Dementia, PD-MCI PD with mild cognitive impairment, PD no-MCI PD with no cognitive impairment, HC healthy controls, MDS-UPDRS III Movement Disorders Society-Unified Parkinson’s disease Rating Scale, motor scale, LEDD levodopa equivalent daily dose, BDI Beck’s Depression Inventory, BAI Beck’s Anxiety Inventory
  2. ^ = mean ± standard deviation; * = p < .05 PDD vs HC; # = p < .05 PDD vs PD no-MCI; % = p < .05 PDD vs PD-MCI; ** = p < 0.05 HC vs All PD groups; NS = not significant